Anika Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anika Therapeutics şirketinin toplam hissedar öz sermayesi $179.9M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $231.4M ve $51.5M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$62.37m
Eşitlik	US$179.86m
Toplam yükümlülükler	US$51.54m
Toplam varlıklar	US$231.41m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: AKP 'nin kısa vadeli varlıkları ( $136.1M ) kısa vadeli yükümlülüklerini ( $25.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: AKP şirketinin kısa vadeli varlıkları ( $136.1M ) uzun vadeli yükümlülüklerini ( $26.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: AKP borçsuzdur.

Borcun Azaltılması: AKP un 5 yıl önce borcu yoktu.

Borç Kapsamı: AKP un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: AKP şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Anika Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Now 41% undervalued after recent price drop

Third quarter 2024 earnings released: US$2.03 loss per share (vs US$0.45 loss in 3Q 2023)

Anika Therapeutics, Inc. Reports Impairment Charges for the Third Quarter Ended September 30, 2024

Anika Therapeutics, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: US$0.006 loss per share (vs US$0.19 loss in 2Q 2023)

Anika Therapeutics, Inc. Affirms Earnings Guidance for the Fiscal Year 2024

Anika Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Anika Therapeutics, Inc. Announces Full Market Release of the Integrity Implant System, a Regenerative Hyaluronic Acid-Based Scaffold for Rotator Cuff and Other Tendon Repairs

Anika Therapeutics, Inc., Annual General Meeting, Jul 09, 2024

Anika Therapeutics, Inc. (NasdaqGS:ANIK) announces an Equity Buyback for $40 million worth of its shares.

Anika Therapeutics, Inc. (NasdaqGS:ANIK) announces an Equity Buyback for $40 million worth of its shares.

Anika Therapeutics, Inc. Announces Board Changes

First quarter 2024 earnings released: US$0.31 loss per share (vs US$0.71 loss in 1Q 2023)

Anika Therapeutics, Inc. Announces CFO Changes

Anika Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024

Full year 2023 earnings released: US$5.64 loss per share (vs US$1.02 loss in FY 2022)

Anika Therapeutics, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Anika Therapeutics, Inc. to Report Q4, 2023 Results on Mar 13, 2024

Anika Therapeutics, Inc. Announces First Surgeries Performed Using the Integrity Implant System

Anika Therapeutics, Inc. Revises Revenue Guidance for the Fiscal Year 2023

Third quarter 2023 earnings released: US$0.45 loss per share (vs US$0.29 loss in 3Q 2022)

Anika Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Anika Therapeutics, Inc. Receives 510(k) Clearance for Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Augmentation of Rotator Cuff Repairs

Second quarter 2023 earnings released: US$0.19 loss per share (vs US$0.20 loss in 2Q 2022)

Anika Therapeutics, Inc. Revises Revenue Guidance for the Fiscal Year 2023

Anika Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Anika Therapeutics, Inc. announces Completed Enrollment of the Pivotal Phase III Clinical Study for Hyalofast (Hyalofast 15-01) on Its Path to Achieving FDA Approval in the United States

First quarter 2023 earnings released: US$0.71 loss per share (vs US$0.20 loss in 1Q 2022)

Anika Therapeutics, Inc. Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: US$1.02 loss per share (vs US$0.29 profit in FY 2021)

Third quarter 2022 earnings released: US$0.29 loss per share (vs US$0.039 profit in 3Q 2021)

Anika Therapeutics, Inc. Provides Revenue Guidance for the Fiscal Year 2022

Anika Therapeutics, Inc.’s Cingal® Successfully Achieves Primary Endpoint in Third Phase III Study

Anika Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Anika Announces First Surgeries Performed Using the X-Twist Fixation System and Commences Limited Market Release

Second quarter 2022 earnings released: US$0.20 loss per share (vs US$0.45 profit in 2Q 2021)

Anika Therapeutics, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Anika Receives FDA 510(k) Clearance for the X-Twist Knotless Fixation System, Expanding its Sports Medicine Soft Tissue Portfolio

First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.20 profit in 1Q 2021)

Anika Therapeutics, Inc. Provides Revenue Guidance for the Year 2022

Anika Therapeutics, Inc. to Report Q1, 2022 Results on May 05, 2022

President recently bought €189k worth of stock

Anika Therapeutics, Inc. Provides Revenue Guidance for Fiscal 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Anika Therapeutics, Inc. to Report Q4, 2021 Results on Mar 08, 2022

Third quarter 2021 earnings released: EPS US$0.039 (vs US$0.45 loss in 3Q 2020)

Anika Therapeutics, Inc. Receives an Additional 510(K) Clearance by the Fda for Tactoset® Injectable Bone Substitute

Second quarter 2021 earnings released: EPS US$0.45 (vs US$0.54 loss in 2Q 2020)

Anika Therapeutics, Inc. Revises Earnings Guidance for the Year 2021

Anika Therapeutics, Inc. Announces First Anika Wristmotion Total Wrist Arthroplasty Surgery Performed

Independent Director Joseph Bower has left the company

Anika Therapeutics, Inc. Provides Earnings Guidance for the Year 2021

Independent Director recently sold €71k worth of stock

First quarter 2021 earnings released: EPS US$0.20 (vs US$0.41 in 1Q 2020)

Anika Therapeutics, Inc. Provides Earnings Guidance for the Year 2021

Full year 2020 earnings released: US$1.69 loss per share (vs US$1.93 profit in FY 2019)

Revenue misses expectations

New 90-day low: €29.20

Anika Therapeutics, Inc. to Report Q4, 2020 Results on Mar 04, 2021

New 90-day high: €34.00

Independent Director recently sold €107k worth of stock

New 90-day low: €27.60

Third quarter 2020 earnings released: US$0.45 loss per share

Revenue beats expectations

Anika Therapeutics, Inc. Suspends Financial Guidance for the Full Year 2020

First half earnings released

Anika Therapeutics, Inc. to Report Q2, 2020 Results on Jul 30, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin